title: [Chemotherapy of non-small cell bronchial cancer with ifosfamide in combination with cisplatin, etoposide or vindesine].
abstract: 192 untreated patients with a histologically verified non-small cell lung carcinoma were treated within 3 phase-II studies with different chemotherapy regimens: ifosfamide 2 g/m2 day 1-5 and cis-platinum 75 mg/m2 on day 1 (study I); ifosfamide 2 g/m2 days 1-5 and etoposide 120 mg/m2 days 1-3 (study II); ifosfamide 2 g/m2 days 1-5 and vindesine 3 mg/m2 on days 1 and 8 (study III). All chemotherapy combinations were repeated every 4 weeks. One therapy with at least 2 courses was the minimum criterion for evaluating the remission rate. We observed complete remissions in 5 patients, and partial remissions in 54 patients (remission rate 31%). The median duration of remission was 7 months, the time to progression 5 months. The median survival time of all 192 patients was calculated as 8.5 months. The performance status had a significant influence on the remission state and the survival time of the patients. The sex and age of the patients as well as the extension and the histological type of the tumor had no influence. Concerning the remission rate and the survival time, there was no significant difference between the 3 therapy regimens. Due to the lesser toxicity, the combination ifosfamide/etoposide was the best.
authors.affiliation: Abteilung Innere Medizin/Onkologie, Thoraxklinik Heidelberg/Rohrbach.
authors.forename: P
authors.initials: P
authors.lastname: Drings
authors.forename: H
authors.initials: H
authors.lastname: Becker
authors.forename: H
authors.initials: H
authors.lastname: Bülzebruck
authors.forename: N
authors.initials: N
authors.lastname: Djawid
authors.forename: E
authors.initials: E
authors.lastname: Ruchalla
authors.forename: P
authors.initials: P
authors.lastname: Stiefel
authors.forename: H W
authors.initials: HW
authors.lastname: Tessen
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D018288:Carcinoma, Small Cell / Q000188:drug therapy; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D002945:Cisplatin / Q000008:administration & dosage; D004341:Drug Evaluation; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D014751:Vindesine / Q000008:administration & dosage
chemical_list: D005047:Etoposide; D002945:Cisplatin; D014751:Vindesine; D007069:Ifosfamide
vernacular_title: Die Chemotherapie des nicht-kleinzelligen Bronchialkarzinoms mit Ifosfamid in Kombination mit Cisplatin, Etoposid oder Vindesin.